Cardiovascular Safety of Oral Antidiabetic Agents: The Insulin Secretagogues
- Michael T. Caulfield, MD and
- Kevin D. O’Brien, MD
Abstract
In Brief
This article reviews and dispels concerns about the potential cardiotoxicity of insulin and oral diabetes drugs, specifically the insulin secretagogues, in patients with type 2 diabetes. The authors focus on insulin and the sulfonylurea drugs but also briefly discuss meglitinide analogs.
Footnotes
-
Michael T. Caulfield, MD, is a senior fellow, and Kevin D. O’Brien, MD, is an associate professor in the Division of Cardiology at the University of Washington School of Medicine in Seattle.
-
Note of disclosure: Dr. O’Brien has received honoraria for speaking engagements from Novartis and Aventis. Both companies manufacture secretagogues for the treatment of type 2 diabetes.
- American Diabetes Association
